NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco
California
94080
United States
78 articles with NGM Biopharmaceuticals, Inc.
-
NGM Bio to Present at Two Upcoming Investor Conferences - June 07, 2021
6/7/2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.
-
NGM Bio's aldafermin failed to hit its primary endpoint in its Phase IIB trial because of that, the company decides to shift resources to other programs.
-
NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
5/24/2021
Study did not meet primary endpoint of fibrosis improvement by >1 stage with no worsening of NASH versus placebo
-
NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
5/23/2021
NGM Biopharmaceuticals, Inc. will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin versus placebo in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis.
-
NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results
5/6/2021
Expect to report topline data from Phase 2b ALPINE 2/3 clinical trial of aldafermin in patients with NASH with F2 and F3 liver fibrosis in the second quarter
-
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors
4/28/2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced the nomination of Roger M. Perlmutter, M.D., Ph.D., to stand for election to the company’s board of directors at its June 8, 2021 annual meeting of stockholders.
-
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
3/4/2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the periods ending December 31, 2020.
-
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer
3/2/2021
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has dosed the first patient in an expansion of its ongoing Phase 1b proof-of-concept study of NGM120 in patients with metastatic pancreatic cancer.
-
Clinical Catch-Up: February 8-12
2/15/2021
It was a busy week for clinical trial announcements and news. Here’s a look. -
NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
2/9/2021
-- Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing-- -- CATALINA Phase 2 study of NGM621 in patients with geographic atrophy (GA) currently underway
-
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
1/12/2021
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today outlined its key achievements in 2020 and its strategic priorities for 2021.
-
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
1/6/2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced the pricing of an underwritten public offering of 4,629,630 shares of its common stock at a price to the public of $27.00 per share.
-
NGM Bio Announces Proposed Offering of Common Stock - Jan 04, 2021
1/4/2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock.
-
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors
12/9/2020
LAIR1, through interactions with tumor-associated collagens, may form a stromal checkpoint that imposes signaling-based immune suppression and impedes anti-tumor immunity
-
NGM to Host Virtual R&D Day on December 9, 2020
11/16/2020
Event to showcase NGM’s multi-therapeutic area pipeline,including its oncology portfolio and Geographic Atrophy and NASH programs
-
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
11/13/2020
--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular inflammation or choroidal neovascularization-- --The serum pharmacokinetics (PK) of NGM621 were linear and dose-proportional-- --NGM621 ocular PK/pharmacodynamics (PD) modeling supports potential for up to every eight-week dosing regimen-- --Enrollment of the CATALINA Phase 2 study of NGM621
-
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
11/12/2020
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the quarter ended September 30, 2020.
-
NGM Bio to Present at Three Upcoming Investor Conferences
11/11/2020
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at three upcoming investor conferences.
-
NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual
11/5/2020
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that data from its Phase 1 study of NGM621, a potent anti-complement C3 antibody, will be featured in a poster presentation at the American Academy of Ophthalmology (AAO) 2020 Virtual.
-
NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH
11/4/2020
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that multiple aldafermin presentations, including a late-breaking oral presentation and comprehensive data from its 24-week Phase 2 study (Cohort 4) of aldafermin in patients with non-alcoholic steatohepatitis (NASH), will be featured at AASLD’s The Liver Meeting ® , bei